[redactions made under s47F of the FOI Act]
From:
Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>
Sent:
Monday, 7 February 2022 9:59 AM
To:
Duggan, Geraint
Cc:
Hoffman, Sharon; Goodrick, Stephanie;
Subject:
Re: NHMRC Meetings 2022 [SEC=OFFICIAL]
Thanks Geraint and apologies if I had missed the email with dates.
On 7 Feb 2022, at 9:37 am, Duggan, Geraint <xxxxxxx.xxxxxx@xxxxx.xxx.xx> wrote:
Hi Mark
I write earlier in the year advising of the Council dates for the rest of the triennium, but it sounds
like it didn’t get to you.
The dates are:
26/7 July 2022 23/24 November 2022
29/30 March 2023
26/27 July 2023
29/30 November 2023
27/28 March 2024
26/27 June 2024
(I have included later dates in case you plan to update the guideline).
The procedures for public consultation and submission and submission (stages 3 and 4) are laid out
in the NHMRC procedures and requirements which I urge you and your team to review before you
plan public consultation. Please contact Sharon Hoffman (copied) who can set up a time with the
NHMRC team to run through what happens next. The timelines for the next few months will be very
tight.
You should also put together a list of Australian and international experts unconnected with the
guideline development process that NHMRC can approach for expert review.
Regards
Geraint
From: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>
Sent: Saturday, 5 February 2022 2:56 PM
To: Duggan, Geraint <xxxxxxx.xxxxxx@xxxxx.xxx.xx>
Cc: Hoffman, Sharon <xxxxxx.xxxxxxx@xxxxx.xxx.xx>; Goodrick, Stephanie
<xxxxxxxxx.xxxxxxxx@xxxxx.xxx.xx>;
Subject: Re: NHMRC Meetings 2022 [SEC=OFFICIAL]
Hello Geraint, we are trying to work out timeline. Do you have a meeting date yet for June,
even early, mid or late would help.
Best
1
Mark
On 26 Oct 2021, at 12:21 pm, Duggan, Geraint
<xxxxxxx.xxxxxx@xxxxx.xxx.xx> wrote:
Hi Mark
Unfortunately not yet.
Our new Council has just been appointed and we are expecting dates to be
announced any day now. We have your guideline booked in for a meeting expected
around March 2022, however because of COVID related delays the agenda is very
congested. If there is the possibility that you would submit for a mid‐year meeting
instead (expected in June) it would be helpful to know this asap.
As soon as we get confirmation of Council dates and your preferred date for
submission Sharon (copied) will contact you to go through the next stepsin detail.
Thanks
Geraint
Geraint Duggan
Director, Clinical Guidelines
Research Translation Branch
National Health and Medical Research Council
xxxxxxx.xxxxxx@xxxxx.xxx.xx
+61 3 8866 0403 / 0414 045 550
nhmrc.gov.au
From: Mark Bellgrove <xxxx.xxxxxxxxx@xxxxxx.xxx>
Sent: Tuesday, 26 October 2021 9:55 AM
To: Duggan, Geraint <xxxxxxx.xxxxxx@xxxxx.xxx.xx>;
Subject: NHMRC Meetings 2022
Dear Geraint,
Would you happen to know when the schedule for the NHMRC guideline
review meetings will be for 2022, just to assist our planning?
2
best
Mark
--
PROFESSOR MARK A. BELLGROVE
Director of Research, Turner Institute for Brain and Mental Health
National Health and Medical Research Council (NHMRC) Senior Research Fellow
President, Australian ADHD Professionals Association (AADPA) Ltd
Turner Institute for Brain and Mental Health
School of Psychological Sciences
Monash University
Room 540, 18 Innovation Walk
Clayton Campus, Clayton VIC 3800
Australia
T:
E: xxxx.xxxxxxxxx@xxxxxx.xxx
ORCID: orcid.org/0000-0003-0186-8349
http://www.monash.edu.au/research/profiles/profile.html?sid=1985044&pid=6456
http://www.monash.edu/turner-institute/
I acknowledge the Traditional Owners and Custodians of the lands on which I live and work and
pay my respect to Elders both past and present
This email (including any attached files) is intended only for
the addressee, it may contain confidential information. If you
are not the addressee, you are notified that any transmission,
distribution, printing or duplication of this email is
strictly prohibited. If you have received this email in error
please promptly inform the sender and delete all copies of
this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not
necessarily represent the official position of the National
Health and Medical Research Council.
Please consider the environment before printing this email,
thank you.
This email (including any attached files) is intended only for the
addressee, it may contain confidential information. If you are not the
addressee, you are notified that any transmission, distribution, printing
or duplication of this email is strictly prohibited. If you have received
this email in error please promptly inform the sender and delete all
copies of this e-mail and all attachments.
Unless explicitly attributed, the opinions expressed do not necessarily
represent the official position of the National Health and Medical
Research Council.
Please consider the environment before printing this email, thank you.
3
